KIMS Vs Global Health: Which Healthcare Stock Has Stronger Growth Potential?

Synopsis: Brokerages remain bullish on two leading hospital stocks backed by strong expansion plans, rising healthcare demand, and improving profitability. Let’s explore which stock offers higher upside potential according to analysts: Krishna Institute of Medical Sciences or Global Health.

Brokerages remain positive on two leading hospital stocks, with both expected to benefit from rising healthcare demand and expansion plans. Analysts believe one stock may deliver stronger gains due to aggressive growth and improving margins, while the other is backed for its stable performance and premium healthcare network. Investors are closely watching valuation, future earnings potential, and expansion strategy to decide which healthcare player could offer better upside in the coming months. Here are two healthcare stocks for brokerages with announced target prices

Krishna Institute of Medical Sciences Limited

With a market capitalization of Rs. 30,754.68 crore, the shares of Krishna Institute of Medical Sciences Limited closed at Rs. 759.70 per equity share, down nearly 1.31 percent from its previous day’s close price of Rs. 769.80.

Goldman Sachs, a prominent brokerage firm, has recommended a “Buy” call on Krishna Institute of Medical Sciences Limited with a target price of Rs. 1,025  per share, indicating a downside potential of 34.92 percent from its current price of Rs. 759.70 per share. 

Krishna Institute of Medical Sciences delivered an inline Q4FY26 performance, in line with market expectations. Goldman Sachs remains positive on the company as the strong quarterly execution and steady operational progress continue to strengthen confidence in its medium-term growth outlook. The brokerage believes KIMS is well-positioned to benefit from rising healthcare demand and expansion across key markets.

Goldman Sachs expects KIMS to deliver industry-leading revenue growth of nearly 30 percent CAGR between FY25-28. This growth is likely to be driven by the ramp-up of new hospitals, improving occupancy levels, and better operational efficiencies, supporting sustained earnings growth over the next few years.

Similarly, Emkay Global Financial Services has recommended a “Buy” call on Krishna Institute of Medical Sciences Limited with a target price of Rs. 825  per share, indicating a downside potential of 8.60 percent from its current price. 

Krishna Institute of Medical Sciences continues to receive a constructive outlook from Emkay, which has maintained its BUY recommendation despite some near-term operational pressures. The brokerage noted that Q4 EBITDA came in nearly 1 percent below expectations, primarily due to delays in insurance empanelments at newly commissioned hospitals. These delays remain a key overhang, as they are slowing patient additions and postponing EBITDA breakeven timelines at certain facilities.

Despite these challenges, Emkay highlighted that the overall ramp-up at new hospitals has been satisfactory. The Thane and Mahadevapura units have intermittently achieved breakeven, reflecting improving occupancy and operational traction. Looking ahead, the brokerage expects KIMS to deliver nearly 26 percent revenue CAGR and around 40 percent EBITDA CAGR over FY26-28, driven by scale-up in new units and better efficiencies. Emkay has trimmed FY27 EBITDA estimates by around 6 percent but slightly increased FY28 estimates by nearly 2 percent, reflecting confidence in the company’s longer-term growth outlook.

About the Company:

Krishna Institute of Medical Sciences Limited (KIMS Hospitals) is a publicly listed Indian healthcare company headquartered in Secunderabad, Telangana. Incorporated in 1973, it operates a network of multi-speciality hospitals across southern and central India, providing tertiary and quaternary medical care at scale and relatively affordable costs.

Coming into financial highlights, Krishna Institute of Medical Sciences Limited’s revenue has increased from Rs. 797 crore in Q4 FY25 to Rs. 1,075 crore in Q4 FY26, which has grown by 34.88 percent. The net profit has decreased by 68.87 percent from Rs. 106 crore in Q4 FY25 to Rs. 33 crore in Q4 FY26.

Global Health Limited

With a market capitalization of Rs. 33,324.19 crore, the shares of Global Health Limited closed at Rs. 1,239.50 per equity share, down nearly 0.02 percent from its previous day’s close price of Rs. 1,239.80.

Anand Rathi, a prominent brokerage firm, has recommended a “Buy” call on Global Health Limited with a target price of Rs. 1,400  per share, indicating a downside potential of 12.95 percent from its current price of Rs. 1,239.50 per share. 

Global Health Limited continues to maintain healthy growth momentum, supported by strong performances from its Lucknow and Patna hospitals. Anand Rathi highlighted that FY26 consolidated revenue grew 19 percent year-on-year to Rs. 4,410 crore, while the company added 623 beds during the year. The newly launched Noida facility generated Rs. 90.6 crore revenue but reported an EBITDA loss of Rs. 78.3 crore, which kept overall margins under pressure.

The brokerage remains positive on the company’s long-term outlook as capacity expansion remains on track. Global Health plans to add around 2,700 beds through five new hospitals over the next 3-4 years. Better speciality mix, rising international patient contribution, and improved utilisation are expected to support 15 percent revenue CAGR and 24 percent EBITDA CAGR over FY26-28.

Similarly, Prabhudas Lilladher has recommended a “Buy” call on Global Health Limited with a target price of Rs. 1,450  per share, indicating a downside potential of 16.98 percent from its current price. 

Global Health Limited reported a strong Q4FY26 performance, with EBITDA rising 13 percent YoY to Rs. 253 crore, ahead of estimates due to better growth in developing hospitals like Lucknow and Patna. Excluding the Noida unit, EBITDA growth stood at nearly 24 percent YoY. Revenue increased 25 percent YoY to Rs. 1,160 crore, while ARPOB improved 5 percent YoY to Rs. 66,700 per day due to a better case mix. Losses at the Noida facility also reduced sequentially, reflecting a gradual improvement in operations.

Prabhudas Lilladher remains positive on the company and maintains a BUY rating, expecting strong growth ahead as operational issues at the Lucknow unit ease, and Noida ramps up further from Q2FY27. The company plans to add nearly 3,190 beds over the next 3-4 years, supporting long-term expansion. The brokerage expects EBITDA CAGR of around 24 percent over FY26-28 and has raised FY27 and FY28 EBITDA estimates by 6 percent each.

About the Company:

Global Health Limited is an Indian public company operating in the hospital and medical care sector. Headquartered in New Delhi and founded in 2004, it owns and manages the Medanta network of multi-specialty hospitals across India. The company has become one of India’s prominent healthcare providers known for advanced tertiary and quaternary care.

Coming into financial highlights, Global Health Limited’s revenue has increased from Rs. 931 crore in Q4 FY25 to Rs. 1,159 crore in Q4 FY26, which has grown by 24.49 percent. The net profit has increased by 40.59 percent from Rs. 101 crore in Q4 FY25 to Rs. 142 crore in Q4 FY26.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post KIMS Vs Global Health: Which Healthcare Stock Has Stronger Growth Potential? appeared first on Trade Brains.